Healthcare Industry News: BRCA2
News Release - June 10, 2011
BSD Medical Announces Publication of Study Showing Hyperthermia Increases Effectiveness of Other Cancer Treatments by Preventing Repair of Tumor CellsSALT LAKE CITY--(Healthcare Sales & Marketing Network)-- BSD Medical Corporation (NASDAQ:BSDM ) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that utilize heat therapy to treat cancer, announced today that a study published in the Proceedings of the National Academy of Sciences demonstrated that hyperthermia can be a powerful tool to inhibit the ability of cancer cells to repair the DNA damage caused by radiation or chemotherapy. The researchers reported that the findings have the potential to significantly increase the clinical use of hyperthermia.
The study (Krawczyk, PM, et al., "Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly [ADP-ribose] polymerase-1 inhibition," PNAS, doi: 10.1073/pnas.1101053108, 2011) was reviewed in The Scientist (http://www.the-scientist.com/news/display/58165/). Roland Kanaar, one of the researchers, summarized the study results for The Scientist, "The finding may have immediate applications in cancer therapeutics. It's simple, but it has big implications."
The findings suggest that the addition of hyperthermia could expand the use of a number of promising new cancer drugs. Efficient DNA repair mechanisms protect cancer cells from the effects of many anti-cancer therapies, thereby reducing the effectiveness of these therapies. The data showed that hyperthermia could reduce the tumor resistance sometimes observed with these anti-cancer therapies, thus increasing their effectiveness.
About Proceedings of the National Academy of Sciences (PNAS) and The Scientist
PNAS is one of the world's most-cited multidisciplinary scientific serials. PNAS publishes cutting-edge research reports. The Scientist is a news magazine that publishes highly rated biology and life sciences research papers. The Scientist is an online guide to the most important advances in the life sciences.
About BSD Medical Corporation
BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for many years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to ablate and destroy soft tissue. The Company has developed extensive intellectual property, multiple products in the market and established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com.
Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.
Source: BSD Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.